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Introduction
Th   e concept of osteoimmunology emerged more than a 
decade ago and is based on rapidly growing insight into 
the functional interdependence between the immune 
system and bone at the anatomical, vascular, cellular, and 
molecular levels [1]. In 1997, the receptor activator of the 
nuclear factor-kappa-B ligand (RANKL)/RANK/osteo-
protegerin (OPG) pathway was identiﬁ   ed as a crucial 
molecular pathway of the coupling between osteoblasts 
and osteoclasts [2]. It appeared that not only osteoblasts 
but also activated T lymphocytes, which play a crucial 
role in the pathogenesis of rheumatoid arthritis (RA), and 
many other inﬂ   ammatory cells can produce RANKL, 
which stimulates the diﬀ   erentiation and activation of 
osteoclasts [3]. Th  ese ﬁ  ndings have contributed to the 
birth of osteoimmunology as a discipline.
Because of the multiple interconnections and inter-
actions of bone and the immune system, bone is a major 
target of chronic inﬂ   ammation in RA and ankylosing 
spondylitis (AS). Inﬂ  ammation increases bone resorption 
and results in suppressed local bone formation in RA and 
locally increased bone formation in AS, causing a wide 
spectrum of bone involvement in RA and AS [4,5].
Osteoporosis has been deﬁ   ned as a bone mineral 
density (BMD) of lower than 2.5 standard deviations of 
healthy young adults and in daily practice is measured by 
dual-energy x-ray absorptiometry (DXA) at the spine and 
hip [6]. However, the bone disease component in RA and 
AS is much more complex, especially around the sites of 
inﬂ  ammation. We reviewed the literature on the quanti-
ﬁ   cation of local and general bone changes and their 
relation to the structural damage of bone, disease activity 
parameters, and fracture risk in the context of osteo-
immunology, both in RA and AS. We have chosen to 
focus on RA and AS since these inﬂ  ammatory rheumatic 
diseases have the highest prevalence and since, in both 
diseases, characteristic but diﬀ   erent types of bone 
involve  ment may occur.
Anatomical and molecular cross-talk between 
bone and the immune system
Multiple anatomical and vascular contacts and overlap-
ping and interacting cellular and molecular mechanisms 
are involved in the regulation of bone turnover and the 
immune system, so that one can no longer view either 
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immune system to be an integrated whole [4,5].
Anatomical connections
Bone, by virtue of its anatomy and vascularization, is at 
the inside and outside and is in direct and indirect and in 
close and distant contact with the immune system. At the 
inside, bones are the host for hematopoiesis, allowing 
bone and immune cells to cooperate locally. At the 
outside, bone is in direct contact with the periost, the 
synovial entheses within the joints at the periost- and 
cartilage-free bare area [7], the ﬁ  brous tendon entheses, 
the calciﬁ  ed component of cartilage and tendon inser-
tions, and the intervertebral discs.
Until recently, it was thought, on the basis of plain 
radiographs of the hands, that there is only rarely a direct 
anatomical connection between bone marrow and joint 
space. Bone erosions have been found in hand joints of 
presumably healthy controls in less than 1% with plain 
radiology and in 2% with MRI [8]. However, exciting new 
data have shown that, with the use of high-resolution 
quantitative computer tomography (HRqCT), small 
erosions (<1.9 mm) in the metacarpophalangeal (MCP) 
joints can be found in 37% of healthy subjects without 
any signs or symptoms of RA, indicating that small 
erosions are not speciﬁ   c for RA [9]. Large erosions 
(>1.9 mm) were found to be speciﬁ  c for RA. Interestingly, 
58% of erosions detected by HRqCT in healthy volunteers 
were not visible on plain radiographs [9]. In healthy 
controls, the erosions in the MCP joints were not 
randomly located but were located at the bare area and at 
high-pressure points adjacent to ligaments, which are 
erosion-prone sites in RA [10]. Bone erosions are also 
extremely common in healthy controls in the entheses 
[11] and in the vertebral cortices covered by periost and 
the intervertebral discs (in AS) [12]. Th   e immune system, 
bone, and its internal and external surfaces not only are 
connected by these local anatomical connections but also 
are connected with the general circulation by the main 
bone nutrition arteries and locally with the periost (by its 
vasculature that perforates cortical bone) and within the 
bone compartment by attachments of ﬁ  brous entheses 
and the calciﬁ   ed components of cartilage and ﬁ  bro-
cartilage up to the tidemark, which separates calciﬁ  ed 
from non-calciﬁ  ed components of cartilage and tendons 
[11].
Molecular connections
Bone cells exert major eﬀ  ects on the immune system. 
Bone cells interact with immune cells and play an 
essential role in the development of the bone marrow 
space during growth [13] and during fracture healing 
[14]. Osteoblasts play a central role in the regulation of 
renewal and diﬀ  erentiation of hematopoietic stem cells 
(HSCs) and of B cells in niches near the endosteum [15-
17]. Metabolic pathways of the osteoblast which are in-
volved in bone remodeling are also involved in the regu-
lation of HSCs by osteoblasts, such as the calcium 
receptor, parathyroid hormone (PTH), bone morpho-
genetic proteins (BMPs), the Wnt signaling, and cell-cell 
interactions by the NOTCH (Notch homolog, trans-
location-associated (Drosophila)) signaling pathway 
[15-19]. On the other hand, multiple cytokines, chemo-
kines, and growth factors of immune cells such as T and 
B cells, ﬁ   broblasts, dendritic cells, and macrophages 
directly or indirectly regulate osteoblast and osteoclast 
activity by producing or inﬂ  uencing the production of 
the RANKL/RANK/OPG pathway, tumor necrosis 
factor-alpha (TNFα), interferon-gamma (IFNγ), and 
inter  leukins (such as IL-1, IL-6, IL-15, IL-17, IL-18, and 
IL-23) and the Wnt signaling with involvement of 
Dikkoppf (DKK), sclerostin, and BMP [4,5,19-21].
In RA, bone loss and bone destruction are dependent 
on the imbalance between osteoclastogenic and anti-
osteoclastogenic factors. T-cell inﬁ  ltration in the syno-
vium is a hallmark of RA. TH17 cells, whose induction is 
regulated by dendritic cells that produce transforming 
growth factor-beta, IL-6, and IL-23, secrete IL-17, which 
induces RANKL in ﬁ   broblasts and activates synovial 
macrophages to secrete TNFα, IL-1, and IL-6, which 
directly or indirectly (via ﬁ  broblasts producing RANKL) 
activate osteoclastogenesis [1]. Other direct or indirect 
osteoclastogenic factors include monocyte/macrophage 
colony-stimulating factor, IL-11, IL-15, oncostatin M, 
leukemia inhibitor factor, and prostaglandins of the E 
series (PGE) [22-24]. Inhibitors of osteoclastogenesis in 
RA include TH1 (producing IFNγ) and TH2 (producing 
IL-4) cells and possibly T helper regulatory (THREG) cells 
[1].
In AS, increased bone formation, as reﬂ  ected  by 
syndesmophyte formation in the spine, is related to 
decreased serum levels of DKK [25] and sclerostin [21], 
both inhibitors of bone formation, and to serum levels of 
BMP, which is essential for enchondral bone formation 
[26], and of CTX-II [27], which reﬂ  ects cartilage destruc-
tion that occurs during enchondral bone formation in 
syndesmophytes [26-28]. Th   ere is, thus, increasing 
evidence that immune cells and cytokines are critically 
responsible for the changes in bone resorption and 
forma  tion and vice versa, resulting in changes in bone 
quality in chronic inﬂ  ammatory conditions. Th  ese  condi-
tions include RA, spondylarthopathies (SpAs) (AS, 
psoriatic arthritis, and inﬂ   ammatory bowel disease), 
systemic lupus erythematosis, juvenile RA, periodontal 
diseases, and even postmenopausal osteoporosis [29]. We 
reviewed the literature on the quantiﬁ   cation of bone 
involvement in RA and AS. For an in-depth discussion of 
the underlying metabolic pathways, a topic that is beyond 
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reviews [4,5].
Histology of bone in rheumatoid arthritis and 
ankylosing spondylitis
Bone resorption
Bone resorption is increased in RA and AS. In RA, this 
has been demonstrated histologically by the presence of 
activated osteoclasts in the pannus at the site of bone 
erosions [30,31], in the periarticular trabecular and 
cortical bone [32,33], and, in a general way, in sites 
distant from inﬂ  ammation [34]. In AS, osteoclastic bone 
resorption has been demonstrated in the sacroiliac joints 
[35-37].
Th  e introduction of MRI has shed new light on the 
involvement of subchondral bone and bone marrow in 
RA and AS (Figure 1). Periarticular MRI lesions have 
been described technically as bone edema (on short T 
inversion recovery (STIR), indicating that fatty bone 
marrow is replaced by ﬂ  uid) and osteitis (on T1 after IV 
gadolinium) [38] and histo  logi  cally as osteitis as 
inﬂ   ammation has been demon  strated on histological 
examination of these lesions [33]. In joint specimens of 
patients with RA and with MRI signs of bone edema, 
histological correlates have been studied in specimens 
obtained at the time of joint replacement and have shown 
the presence of greater numbers of osteo  clasts than in 
controls and in patients with osteoarthritis and the 
presence of T cells, B-cell follicles, plasma cells, 
macrophages, decreased trabecular bone density, and 
increased RANKL expression [33].
Osteitis is also a major component of AS [39-42]. 
Osteitis was described by histology of the vertebrae in 
1956 [43] and occurs early in the disease and predicts the 
occurrence of bone erosions [39]. It has been shown that, 
as in RA, these lesions contain activated immune cells 
and osteoclasts [44,45]. In contrast to RA, these lesions 
diﬀ  er in their location: in the vertebrae, the entheses, the 
periost of vertebrae and around the joints, the disco-
vertebral connections, the intervertebral joints and the 
sacroiliac joints, and, to a lesser degree, the peripheral 
joints, mainly hips and shoulders (Figure 1) [46,47].
Bone formation
In spite of the presence of cells with early markers of 
osteoblasts in and around erosions in RA, bone formation 
is locally suppressed [48]. Th  is uncoupling of bone 
resorption and bone formation contributes to the only 
rare occurrence of healing bone erosions [49] and results 
in persisting direct local connections between the joint 
cavity and subchondral bone and thus between synovitis 
and osteitis. In contrast, in AS, local peri-inﬂ  ammatory 
bone formation is increased, resulting in healing of 
erosions, ossifying enthesitis, and potential ankylosis of 
sacroiliac joints and of intervertebral connections. Th  e 
ossiﬁ   cation of entheses and sacroiliac joints involves 
calciﬁ  cation of the ﬁ  brocartilage, followed by enchondral 
bone formation; that is, calciﬁ  ed cartilage is replaced by 
bone through osteoclastic resorption of calciﬁ  ed cartilage 
and deposition of bone layers on the inside of the 
resorption cavity with a very slow evolution and with 
prolonged periods of arrest [50].
Bone biomarkers
In patients with RA, markers of bone resorption are 
increased in comparison with controls [51]. Correlations 
between bone markers, bone erosions, and bone loss in 
RA varied according to study designs (cross-sectional or 
longitudinal), patient selection, and study endpoints 
(disease activity score, radiology, and MRI) [52]. Baseline 
markers of bone and cartilage breakdown (CTX-I and 
CTX-II) and the RANKL/OPG ratio were related to 
Figure 1. Osteitis in rheumatoid arthritis (RA) (in metacarpophalangeal joint) and in ankylosing spondylitis (AS) (in the sacroiliac joint 
and in vertebra).
Osteitis
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progression of joint damage in RA, independently of 
other risk factors of bone erosions [53,54]. Increased 
markers of bone resorption were related to increased 
fracture risk [49]. Studies on markers of bone formation 
in RA, such as osteocalcin, are scarce and show 
contradictory results, except low serum values in 
glucocorticoid (GC) users [55,56].
In AS, markers of bone resorption were increased 
[27,57] and were related to inﬂ  ammation as measured by 
serum IL-6 [58]. Increased serum levels of RANKL have 
been reported [59] with decreased OPG [60,61], and 
RANKL expression is increased in peripheral arthritis of 
SpA [62]. Markers of bone formation (type I collagen N-
terminal propeptide, or PINP) were related to age, 
disease duration, and markers of bone resorption 
(CTX-I) but not with low BMD in the hip or spine [63]. 
Markers of cartilage breakdown (CTX-II) were related to 
progression of the modiﬁ  ed Stoke Ankylosing Spondylitis 
Spine Score (mSASSS) and the appearance of syn  des-
pomphytes [27].
Imaging of bone in rheumatoid arthritis and 
ankylosing spondylitis
Many methods, including histomorphometry, imaging 
(Figure 2), and biomarkers, have been used to study the 
eﬀ   ect of inﬂ   ammation on structural and functional 
aspects of bone in RA and AS. Conventional radiology of 
the peripheral joints and the spine is used for identifying 
erosions, joint space narrowing, enthesitis, and syn  des-
mo  phytes for diagnosis; assessment of disease progres-
sion; and standardized scoring in clinical trials, but it is 
estimated that bone loss of less than 20% to 40% cannot 
be detected on plain radiographs [64].
Methods that quantify changes in periarticular bone 
include radiogrammetry, digitalized radiogrammetry 
(DXR) [65], peripheral dual-energy x-ray absorptiometry 
(pDXA) [66], quantitative ultrasound (QUS) [67], high-
resolution digital radiography [68], high-resolution peri-
pheral qCT [9], and MRI [8], and methods that quantify 
changes in the vertebrae include DXA, qCT, MRI, and 
morphometry by vertebral fracture assessment on x-rays 
or DXA images [69] (Figure 2). At other sites of the 
skeleton, single x-ray absorptiometry, qCT, MRI, DXA, 
and QUS are available; of these, DXA is considered the 
gold standard [70]. Semiquantitative scoring of osteitis 
on MRI in the vertebrae has been standardized [40,42,71]. 
Local peri-inﬂ  ammatory bone formation can be evalu-
ated semiquantitatively in a standardized way on radio-
graphs for scoring of syndesmophytes [41,42,72]. Th  ese 
techniques diﬀ   er in regions of interest that can be 
measured, in the ability to measure cortical and trabe-
cular bone separately or in combination, and in radiation 
dose, cost, and precision [64,73] (Table 1).
Periarticular bone loss and osteitis in rheumatoid 
arthritis
On plain radiographs of the hands, periarticular trabe  cu-
lar bone loss results in diﬀ  use or spotty demineralization 
and blurred or glassy bone and cortical bone loss in 
tunneling, lamellation, or striation of cortical bone [74] 
(Figure 3). Quantiﬁ  cation of bone in the hands has con-
sis  tently shown that patients with RA have lower BMD 
than controls and lose bone during follow-up, depending 
on treatment (see below) [75-77]. Cortical bone loss 
occurs early in the disease, preferentially around aﬀ  ected 
joints and before generalized osteoporosis can be 
detected [51,78]. In studies using peripheral qCT at the 
forearm, trabecular bone loss was more prominent than 
cortical bone loss in RA patients using GCs [79,80].
Hand bone loss is a sensitive outcome marker for radio-
logical progression. Th   e 1-year hand bone loss measured 
by DXR predicted the 5- and 10-year occurrence of 
erosions in RA [73,81] and was a useful predictor of the 
bone destruction in patients with early unclassiﬁ  ed 
polyarthritis [82]. Hand bone loss measured by DXR 
correlated with C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), disease activity score using 28 
joint counts (DAS28), the presence of rheumatoid factor 
(RF) and anti-cyclic citrullinated peptide antibody (anti-
CCP), health assessment questionnaire (HAQ) score, 
disease duration, and Sharp score [66,83,84]. In the fore-
arm and calcaneus, trabecular but not cortical peri-
articular bone loss measured by DXA in early RA corre-
lated with ESR, CRP, RF, and HAQ score [80]. DXR 
correlated with hip BMD and the presence of morpho-
metric vertebral fractures and non-vertebral fractures in 
RA [85]. DXR-BMD performed as well as other peri-
pheral BMD measurements for prediction of wrist, hip, 
and vertebral fractures in the Study of Osteoporotic 
Fractures [86].
Periarticular osteitis is a frequent ﬁ  nding in RA (45% to 
64% of patients with RA) and has remarkable similarities 
with periarticular bone loss in RA (Figure 1) [87]. Osteitis 
is found early in the disease process, is predictive of 
radiographic damage, including erosions and joint space 
narrowing, SF-36 (short-form 36-question health survey) 
score function, and tendon function, and is related to 
clinical parameters CRP and IL-6 in early RA and to 
painful and aggressive disease [87-94]. Scoring of MRI 
edema has been standardized by OMERACT (Outcome 
Measures in Rheumatoid Arthritis Clinical Trials) [88]. 
Osteitis is characterized by trabecular bone loss on his-
tology [66,84-96], but no studies on the relation between 
osteitis and quantiﬁ  cation of bone loss were found.
Generalized bone loss in rheumatoid arthritis
BMD is a major determinant of the risk of fractures, but 
the relationship between BMD and fracture risk is less 
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indicat  ing that factors other than those captured by 
measuring BMD are involved in the pathophysiology of 
fractures in RA.
Patients with RA have a decreased BMD in the spine 
and hip and consequently have a higher prevalence of 
osteoporosis [56,97-101]. However, this was not con-
ﬁ  rmed in the Canadian Multicentre Osteoporosis Study 
(CaMos) [102]. In early untreated RA, BMD was related 
to longer symptom duration, the presence of RF [103] 
and anti-CCP [104], disease activity score [105], and the 
presence and progression of joint damage [106].
Th  e interpretation of longitudinal changes in RA is 
complicated by the lack of untreated patients, and this 
limits our insights into the natural evolution of bone 
changes in RA to the above-mentioned studies. In one 
study with early untreated RA, bone loss was found in 
the spine and trochanter for a period of one year [107]. 
However, Kroot and colleagues [108] did not ﬁ  nd bone 
loss over the course of a 10-year follow-up in RA patients 
treated with disease-modifying anti  rheumatic drugs, 
except when these patients were treated with GCs. 
Generalized bone loss was related to joint damage in 
some studies [109,110], but this relation dis  appeared after 
multivariate adjustment [111]. No correla  tion between 
BMD and the presence of vertebral frac  tures in RA 
patients treated with GCs was found [112].
Fracture risk in rheumatoid arthritis
In the largest epidemiological study, patients with RA 
were at increased risk for fractures of osteoporotic 
fractures (relative risk (RR) 1.5), fractures of the hip (RR 
2.0), clinical vertebral fractures (RR 2.4), and fractures of 
the pelvis (RR 2.2) [113]. Th  e risk of morphometric 
vertebral fractures was also increased [114,115]. In some 
but not all studies, the risk of fractures of the humerus 
(RR 1.9), wrist (RR 1.2), and tibia/ﬁ  bula (RR 1.3) was 
increased [75,116,117].
Th  e etiology of increased fracture risk in RA is 
multifactorial and superimposed on and independent of 
Figure 2. Methods to quantify bone changes in the hands and vertebrae. (a) Methods to quantify periarticular bone changes. (b) Methods 
to quantify vertebral bone changes. μCT, micro-computed tomography; DXA, dual-energy x-ray absorptiometry; DXR, digitalized radiogrammetry; 
HRDR, high-resolution digital radiology; MRI, magnetic resonance imaging; QCT, quantitative computer tomography; QUS, quantitative ultrasound; 
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ing the use of GCs. RA is included as an independent 
clinical risk factor for 10-year fracture risk calculation for 
major and hip fractures in the fracture risk assessment 
tool (FRAX) case-ﬁ   nding algorithm [118]. Stress frac-
tures have been found in 0.8% of patients with RA, can be 
diﬃ   cult to diagnose, and were related to GC use but not 
to BMD [119].
Fracture risk in RA was related to the duration of RA 
[120], the severity of disease, and its musculoskeletal 
conse  quences, such as disability, HAQ score, lack of 
physical activity, and impaired grip strength [120-122]. 
Vertebral fractures were related to disease duration and 
severity [69]. In the general population, fracture risk was 
related to serum levels of IL-6, TNF, and CRP [123] and 
parameters of bone resorption [124], all of which can be 
increased in RA. Extraskeletal risk factors that inﬂ  uence 
fracture risk include increased risk of fall rates which 
were related to number of swollen joints and impaired 
balance tests [125].
Risk predictors of bone changes in rheumatoid 
arthritis
Currently, the most widely used case-ﬁ  nding algorithm 
for calculating the 10-year fracture risk for major and hip 
fractures is the FRAX tool [118]. FRAX includes RA as a 
risk for fractures, independently of and superimposed on 
other risk factors, including BMD and use of GCs [118]. 
No fracture risk calculator that also includes other risk 
factors that are related to RA, such as disease duration 
and disease severity, is available. Th   e Garvan fracture risk 
calculator (GFRC) can be used to calculate the 5- and 
10-year fracture risk which includes the number of recent 
falls and the number of previous fractures but lacks RA 
as a risk factor [126]. Fracture risk is higher with GFRC 
than with FRAX in patients with recent falls [126]. In 
view of the increased fracture risk in patients with RA, 
systematic evaluation of fracture risk should be 
considered using FRAX, disease severity, and duration, 
and GFRC is helpful when patients report recent falls. 
Risk of low BMD is diﬃ   cult to estimate in RA [90], and 
this suggests that bone densito  metry should also be 
considered in fracture risk calculation in patients with 
active RA [127]. Many risk factors, including baseline 
disease severity, RF, anti-CCP, baseline bone destruction, 
the RANKL/OPG ratio, and CTX-I and CTX-II, have 
been identiﬁ  ed for the prediction of bone erosions in RA. 
Th  is pallet of predictors can now be extended with 
measurement of changes in periarticular bone (by DXR) 
and osteitis (on MRI) early in the disease [73,81,82]. 
Additional studies will be necessary to study the relation 
between osteitis and bone loss.
Table 1. Techniques to assess hand bone damage in rheumatoid arthritis
 Studied  features  Advantages  Disadvantages
CR  Bone erosion  Gold standard  Low sensibility
  Joint space narrowing  Easy accessibility  No evaluation of bone density
    Low cost  Ionizing radiation
   High  specifi   city
MRI  Bone erosion  Early detection of bone erosions  Expensive
  Bone edema  Prediction of erosive progression  Uncomfortable
  Synovitis  Monitoring bone change  No evaluation of bone density
  Tenosynovitis  Measurement of erosion volume
    Absence of radiation exposure
CT  Bone erosion  High resolution  No evaluation of bone density, synovitis, and bone edema
     Ionizing  radiation
US  Bone erosion  Non-invasiveness  No evaluation of bone edema
  Synovitis  Easy accessibility  Sensibility depending on joint accessibility
 Tenosynovitis Low  cost
  Bone density  Monitoring bone change  Operator-dependent
    Investigating cortical and trabecular bone separately
    Absence of radiation exposure
DXA  Bone density  Early detection of bone damage  No evaluation of bone erosion, bone edema, and synovitis
   Small  eff  ective radiation dose
DXR  Bone density  Better reproducibility than DXA  No evaluation of bone erosion, bone edema, and synovitis
    Higher sensitivity than DXA  Ionizing radiation
    Predictive of erosive disease
CR, computed radiography; CT, computed tomography; DXA, dual-energy x-ray absorptiometry; DXR, digitalized radiogrammetry; MRI, magnetic resonance imaging; 
US, ultrasound. Reprinted with permission from Elsevier [73].
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arthritis
As the pathophysiology of bone loss in RA is taken into 
account (Figure 4), therapy should be directed at suppres-
sing inﬂ   ammation and bone resorption and restoring 
bone formation. No randomized placebo-controlled 
trials (RCTs) on the eﬀ  ect of treatment on fracture risk in 
RA are available. However, the available data suggest that 
control of inﬂ  ammation (TNF blockade and appropriate 
dose of GCs), speciﬁ   c inhibition of bone resorption 
(bisphosphonates and denosumab), strontium ranelate, 
and restoration of the balance between bone resorption 
and formation (teriparatide and PTH) are candidates for 
such studies. Bone loss early in the disease continued 
despite clinical improvement and suﬃ   cient  control  of 
inﬂ  ammation through treatment, indicating a disconnect 
between clinical inﬂ  ammation and intramedullary bone 
loss [128]. However, these studies did not include TNF 
blockers, and, at that time, remission was not a realistic 
tool of therapy. Suppression of inﬂ  ammation with TNF 
blockers such as inﬂ  iximab and adalimumab decreased 
markers of bone resorption and the RANKL/OPG ratio 
[129], decreased osteitis, and reduced or arrested 
generalized (in spine and hip) bone loss [75]. Inﬂ  iximab, 
however, did not arrest periarticular bone loss [129]. In 
the Behandelstrategieën voor Reumatoide Artritis (BEST) 
study, both bone loss at the metacarpals and radiographic 
joint damage were lower in patients adequately treated 
with combination therapy of methotrexate plus high-
dose prednisone or inﬂ   iximab than in patients with 
suboptimal treatment [130].
Several pilot studies on the eﬀ  ect  of  antiresorptive 
drugs on bone in RA have been performed. Pamidronate 
reduced bone turnover in RA [131]. Zoledronate decreased 
the number of hand and wrist bones with erosions [132]. 
Denosumab strongly suppressed bone turnover and, in 
higher dosages than advocated for the treatment of 
postmenopausal ostepororotic women, prevented the 
occurrence of new erosions and increased BMD in the 
spine, hip, and hand, without an eﬀ  ect on joint space 
narrowing and without suppressing inﬂ  ammation, 
indicating an eﬀ   ect on bone metabolism but not on 
cartilage metabolism [133-136].
Th  e  eﬀ  ects of GCs on bone loss and fracture risk in RA 
should be interpreted with caution as GCs have a dual 
eﬀ   ect on bone in RA. On the one hand, controlling 
inﬂ   am  mation with GCs strongly reduces bone loss, 
whereas, on the other hand, GCs enhance bone 
resorption, suppress bone formation, and induce osteo-
cyte apoptosis.
Studies in glucocorticoid-induced osteoporosis 
(GIOP) included patients with RA. None of these 
studies had fracture prevention as a primary endpoint, 
and no data on the GIOP studies on fracture prevention 
in RA separately are available (see [137] for a recent 
review). RCTs in GIOP showed that bisphosphonate 
treatment (alendronate, risedronate, and zoledronate) 
and teripara  tide prevented bone loss and increased 
BMD. Alendro  nate and risedronate decreased the risk 
of vertebral fractures versus placebo and teriparatide 
versus alendro  nate. No convincing evidence on fracture 
risk in GIOP for calcium and vitamin D supplements 
(calcitriol or alfacalcidol) is available. However, most 
RCTs in GIOP provided calcium and vitamin D 
supplements. Most guide  lines, therefore, advocate 
calcium and vitamin D supple  ments, bisphosphonates, 
and eventually teripara  tide as a second choice because 
of its higher cost price in the prevention of GIOP in 
patients at high risk, such as those with  persistent 
disease activity, high dose of GCs, or high background 
risk such as menopause, age, low BMD, and the 
presence of clinical risk factors [138,139].
Taken together, these data indicate that control of 
inﬂ   am  mation is able to halt bone loss and suppress 
osteitis in RA. Bisphosphonates are the front-line choice 
for fracture prevention in GIOP, but in patients with a 
very high fracture risk, teriparatide might be an attractive 
alternative. Th  e  eﬀ  ect of denosumab indicates that osteo-
clasts are the ﬁ  nal pathway in bone erosions and local 
and generalized bone loss and that the bone destruction 
component of RA can be disconnected from inﬂ  am  ma-
tion by targeting RANKL.
Figure 3. Cortical bone changes in rheumatoid arthritis on 
classical radiography showing striation and lamellation of 
cortical bone of the phalanx.
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Page 7 of 16Generalized bone loss in ankylosing spondylitis
Bone loss in the vertebrae occurs early in the disease, as 
shown by DXA [140] and qCT [141]. In advanced disease, 
the occurrence of syndesmophytes and periosteal and 
discal bone apposition does not allow intravertebral bone 
changes with DXA to be measured accurately. Combined 
analyses of DXA and QCT in patients with early and 
long-standing disease indicate that bone loss in the 
vertebrae occurs early in the disease and can be measured 
by DXA and QCT but that, in long-standing disease, 
DXA of the spine can be normal, in spite of further 
intravertebral bone loss as shown with qCT [142,143]. As 
a result, in early disease, osteoporosis was found more 
frequently in the spine than in the hip, whereas in 
patients with long-standing disease, osteoporosis was 
more frequent in the hip [75]. Hip BMD was related to 
the presence of syndesmophytes and vertebral fractures, 
to disease duration and activity [142,144], and to CRP 
[145]. Osteitis in the vertebrae precedes the development 
of erosions and syndesmophytes [41,42].
Fracture risk in ankylosing spondylitis
Morphometric vertebral fractures (with a deformation of 
15% or 20%) have been reported to be 10% to 30% in 
groups of patients with AS [146]. Th  e odds ratios of 
clinical vertebral fractures were 7.7 in a retrospective 
population-based study [147] and 3.3 in a primary care-
based nested case control study [148]. In both studies, 
the risk of non-vertebral fractures was not increased.
Th  e risk of vertebral fractures is multifactorial and 
inde  pendent of and superimposed on other clinical risk 
factors [118].
Vertebral fracture risk in AS was higher in men than in 
women and was associated with low BMD, disease 
activity, and the extent of syndesmophytes [144,149]. 
Vertebral fractures contributed to irreversible hyper-
kyphosis, which is characteristic in some patients with 
advanced disease with extensive syndesmophytes (bamboo 
spine) [150,151].
Apart from presenting with these ‘classical’ vertebral 
fractures, patients with AS can present with vertebral 
fractures that are speciﬁ   cally reported in AS. First, 
erosions at the anterior corners and at the endplates of 
vertebrae (Andersson and Romanus lesions) result in 
vertebral deformities if erosions are extensive and the 
results of such measurements should not be considered a 
classical vertebral fracture (Figure 5) [75,152]. Second, in 
a survey of 15,000 patients with AS, 0.4% reported 
clinical vertebral fractures with major neuro  logical 
complications [153]. Th   ird, owing to the stiﬀ  ening of the 
spine by syndesmophytes, transvertebral fractures have 
been described [153]. Fourth, fractures can occur in the 
ossiﬁ  ed connections between the vertebrae [153]. In all of 
these cases, CT, MRI, and eventually bone scintigraphy 
are helpful to identify these lesions and the extent of 
neurological consequences (Figure 6) [154].
Risk predictors of bone changes in ankylosing 
spondylitis
Th  e diagnosis of vertebral fractures is hampered by the 
ﬁ  nding that only one out of three morphometric vertebral 
fractures is accompanied by clinical signs and symptoms 
of an acute fracture. Th   is is probably even less in patients 
with AS as fractures of the vertebrae and their annexes 
can be easily overlooked when a ﬂ  are of back pain is 
considered to be of inﬂ  ammatory origin without taking 
into account the possibility of a fracture. In case of a ﬂ  are 
of back pain, special attention, therefore, is necessary to 
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Page 8 of 16diagnose vertebral fractures in AS, even after minimal 
trauma. Additional imaging (CT, MRI, and bone scinti-
graphy) might be necessary in patients in whom a 
fracture is suspected in the absence of abnormalities on 
conventional radiographs. On the basis of the limited 
data on fracture risk in AS, vertebral fractures especially 
should be considered in patients with a ﬂ  are of back pain, 
persistent inﬂ   ammation, long disease duration, hyper-
kyphosis with increased occiput-wall distance, bamboo 
spine, and persistent pain after trauma, even low-energy 
trauma. Th   e FRAX algorithm can be used to calculate the 
10-year fracture risk but cannot be used to separately 
calculate the risk of clinical vertebral fractures [118].
Risk factors to predict erosive sacroiliitis have been 
identiﬁ  ed. Th   ese include male gender, CRP, B27, clinical 
symptoms, family history [155-157], and the occurrence 
of syndesmpophytes (such as B27, uveitis, no peripheral 
arthritis, prevalent syndesmophytes, and disease dura-
tion) [72,158,159]. Also, CTX-II has been shown to 
predict syndesmophytes, which could reﬂ  ect  cartilage 
destruc  tion during enchondral new bone formation in 
enthesitis, including syndesmophytes [27]. Th  ese risk 
factors can now be extended with subchondral bone 
involvement (as deﬁ  ned by osteitis on MRI) that has been 
shown to predict erosive sacroiliitis [39] and the occur-
rence of syndesmophytes [160,161]. To predict radio-
graphic erosive sacro  iliitis, the Assessment of Spondylo-
Arthritis international Society recently developed and 
validated criteria that included active signs of inﬂ  am-
mation on MRI, which are deﬁ  ned as active inﬂ  ammatory 
lesions of sacroiliac joints with deﬁ   nite bone marrow 
edema/osteitis [156,157].
Eff  ect of treatment on bone changes in ankylosing 
spondylitis
As the pathophysiology of vertebral fractures in AS is 
taken into account (Figure 7), therapy should be directed 
at suppressing inﬂ  ammation, bone resorption, and bone 
formation. No RCTs on the eﬀ  ect of treatment on the risk 
Figure 5. Changes in vertebral shapes in ankylosing 
spondylitis. (a) Vertebral deformation in ankylosing spondylitis. Ha, 
anterior height; Hp, posterior height. (b) Vertebral deformation due 




Figure 6. Fracture of dorsal arch and pedicle in a patient with 
ankylosing spondylitis and bamboo spine and persisting back 
pain after minimal trauma.
Geusens and Lems Arthritis Research & Therapy 2011, 13:242 
http://arthritis-research.com/content/13/5/242
Page 9 of 16of vertebral fractures in AS are available. In the General 
Practice Research Database, the use of non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) is associated with a 
30% decrease in the risk of clinical vertebral fractures, 
but this has not been studied prospectively [75,148]. In 
general, continuous use of NSAIDs, in com  parison with 
intermittent use, and celecoxib decreased the formation 
of syndesmophytes [148,162]. Th  e mechanisms of these 
eﬀ  ects are unclear. NSAIDs inhibit bone formation, as 
shown in fracture healing, which is also an inﬂ  ammation-
driven model of increased bone formation [163,164]. One 
other explanation is that pain relief can ameliorate 
function and decrease immobility [75]. Limited studies 
with bisphosphonates indicated inhibi  tion of inﬂ  am  ma-
tion in AS [165]. Zoledronate did not prevent the occur-
rence of syndesmophytes in rats [166]. Bisphosphonates, 
however, can be considered in the treatment of osteo-
porosis in high-risk patients [167]. TNF blockade 
decreased osteitis, prevented bone loss, and decreased 
CRP and IL-6 [145,168] but had no eﬀ   ect on the 
occurrence of syndesmophytes [169]. Taken together, 
these data indicate that control of inﬂ  ammation is able to 
halt bone loss and suppress osteitis in AS but not the 
occurrence of syndesmophytes. Further research is 
needed to understand why NSAIDs could decrease fracture 
risk and syndesmophyte formation, why TNF blockade 
prevents bone loss but not syndesmophyte formation, and 
new ways to prevent syndesmophyte formation.
Discussion and summary
Th   ese data indicate that bone is a major target for inﬂ  am-
mation and that bone loss and osteoporosis are common 
features that contribute to the increased fracture risk in 
RA and AS. However, the problem of bone involvement 
in RA and AS is more complex than in primary osteo-
porosis alone. Th  e consistent ﬁ   nding of peri-inﬂ  am-
matory bone loss and osteitis in both RA and AS raises 
questions, besides fracture risk, about the clinical 
signiﬁ  cance of bone loss.
Periarticular bone loss and osteitis coincide early in RA 
and AS and not only precede but also predict the occur-
rence of visible erosions [76]. Th   is raises the question of 
the mechanism by which these anatomical coincident 
changes in the joints, entheses, and bone marrow occur. 
As described above, no direct anatomical or vascular 
connection between the joint cavity and bone marrow is 
present, but some healthy subjects can have small ero-
sions in the MCP joints without having RA and have 
erosions at the entheses and vertebral cortices. In 
subjects with small erosions before RA or AS becomes 
apparent clinically, it can be assumed that, when they 
develop arthritis or enthesitis, the erosions allow imme-
diate contact with bone marrow, resulting in coincident 
joint, enthesis, and bone marrow inﬂ  ammation. Healthy 
subjects without such erosions could develop small 
erosions, resulting in measurable peri-inﬂ  ammatory 
bone loss, before they can be identiﬁ  ed on radiographs or 
MRI because of the spatial resolution of radiology and 
MRI and the single-plane images of radiographs. Another 
hypothesis is that RA and AS are primarily bone marrow 
diseases [170,171], with secondary invasion of the joint 
via erosions created by intramedullary activated osteo-
clasts or via pre-existing erosions. Indeed, CD34+ bone 
marrow stem cells have been shown to be abnormally 
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Page 10 of 16sensitive to TNFα to produce ﬁ  broblast-like cells [172], 
suggesting an underlying bone marrow stem cell 
abnormality in RA.
In AS, the ﬁ   nding of early osteitis is even more 
intriguing as osteitis is occurring in the vertebrae, where 
no synovium but periost is present at the anterior sites 
and discs between vertebrae. Local communication with 
the periost is possible by the local vascular connections 
or pre-existing erosions, leaving open the possibility that 
periost is the primary location of inﬂ  ammation in AS. 
Th   e same applies for the intervertebral disc, which has no 
direct vascular contact but can have pre-existing ero-
sions. Whether RA and AS are initialized in the joints, 
enthesis, or the bone marrow is a growing ﬁ  eld of debate 
[170], and such hypotheses will need much more study.
Regardless of these anatomical considerations, when 
the size of bone edema that can be found by MRI and the 
extent of early periarticular bone loss are taken into 
account, it seems that inﬂ  ammation is as intense and 
extensive inside bone marrow as in the synovial joint in 
RA and AS and in the enthesis in AS. As bone loss and 
bone edema occur early in the disease, these ﬁ  ndings 
indicate that bone marrow inﬂ  ammation – and not just 
joint or enthesis inﬂ  ammation – is a classical feature of 
early RA and AS. To what degree impaired osteoblast 
function is associated with loss of control of HSC and B-
cell diﬀ  erentiation in their subendosteal niches in RA is 
unknown and needs further study as B-cell proliferation 
is a feature of RA but not of AS [173-175].
Th  e  ﬁ  nding that bone involvement can be disconnected 
from clinically detectable inﬂ  ammation is quite intrigu-
ing. In RA, bone erosions can progress even when the 
inﬂ  ammatory process is adequately controlled (that is, in 
clinical remission) [176], and progress of bone erosions 
can be halted by denosumab in spite of persistent inﬂ  am-
mation [133-136]. In AS, the occurrence of syndesmo-
phytes can progress in spite of suppression of inﬂ  am-
mation by TNF blockade [160]. Th  ese  ﬁ  ndings have been 
described as a disconnection between inﬂ  ammation and 
bone destruction and repair.
Th  e correlation and eventual disconnection between 
osteitis and bone loss, parameters of disease activity, and 
erosions suggest a dual time-dependent role for the 
occurrence of erosions. Early in the disease process, the 
primary negative eﬀ  ect of pre-existing or newly formed 
erosions is the connection they create between the bone 
marrow and the joints, periost, and entheses. In this way, 
erosions contribute to local ampliﬁ  cation of inﬂ  ammation 
by allowing bone marrow cells to have direct local 
connection with extraosseous structures and creating a 
vicious circle of inﬂ   ammation between joints, periost, 
entheses, and bone marrow [177]. Only in a later stage do 
erosions contribute to loss of function [178]. In this 
hypothesis, the attack of inﬂ   ammation on bone by 
stimulating osteoclasts has far-reaching consequences. 
First, it would indicate that timely disease suppression 
and the prevention of the development of a ﬁ  rst erosion 
rather than halting erosion progression should be 
considered a primary objective, both in RA and AS [179]. 
Second, periarticular bone loss and osteitis should be 
considered, at least theoretically, an indication for the 
presence of erosions, even when erosions cannot be 
visualized on radiographs or MRI, and periarticular bone 
loss and osteitis should be considered an indication for 
early aggressive therapy [180]. Of course, the eﬀ  ectiveness 
of antirheumatic treatment based on osteitis should be 
demonstrated. Th   ird, the ﬁ   nding of disconnection 
between inﬂ  ammation and bone involvement indicates 
that, even when inﬂ  ammation is clinically under control, 
the degree to which bone-directed therapy is indicated 
should be studied in order to prevent (further) progres-
sion of erosions and syndesmophytes. In conclusion, the 
involve  ment of bone as a major target of inﬂ  ammation in 
RA and AS raises many questions [10,181-184], opening 
perspectives for further research in the understanding 
and treatment of the complex bone disease component of 
RA and AS.
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